" class="no-js "lang="en-US"> Takeda Pharmaceutical Company - Medtech Alert
Monday, May 27, 2024
Takeda Pharmaceutical Company | Pharmtech Focus

Takeda Pharmaceutical Company

About Takeda Pharmaceutical Company

Takeda Pharmaceutical Company

Takeda has been putting patients first for more than two centuries. We are a global, science-driven biopharmaceutical leader with headquarters in Japan and the U.S., guided by our Patient-Trust-Reputation-Business philosophy. This perspective represents who we are and guides how we act, helping us make decisions we can be proud of today and in the future.

As a member of our team, you’ll help deliver on our mission to strive for better health and a brighter future for people worldwide through leading innovation in medicine. It’s a responsibility that motivates and inspires us all.

You’ll find your own professional inspiration at Takeda, in the area that suits your interests and skills. Whether that’s R&D, Oncology, Corporate, Manufacturing, Quality, or another business unit, wherever you find yourself at Takeda, you’ll enjoy a meaningful career that’s making a positive impact on patients, people and the planet.

Related Story

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

May 26 2023

Takeda and HUTCHMED have announced that the U.S. Food and Drug Administration (“FDA”) has granted […]

First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead

April 4 2023

Arrowhead Pharmaceuticals today announced that the first patient has been dosed in Takeda’s Phase 3 […]

Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib

January 23 2023

Takeda has today announced that it has entered into an exclusive licensing agreement with HUTCHMED […]

HemoShear Develops New Human Tissue-Based Model of Rare Liver Disease Under Research Collaboration with Takeda

August 11 2022

HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has received a milestone payment […]

FDA Approves Tissue-Based NGS Companion Diagnostic for Takeda's Targeted Therapy for NSCLC Patients with EGFR Exon20 Insertion Mutations

September 17 2021

The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific‘s […]